Cargando…
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
Inappropriate signalling through the EGFR and ErbB2/HER2 members of the epidermal growth factor family of receptor tyrosine kinases is well recognised as being causally linked to a variety of cancers. Consequently, monoclonal antibodies specific for these receptors have become increasingly important...
Autores principales: | Robinson, M K, Hodge, K M, Horak, E, Sundberg, Å L, Russeva, M, Shaller, C C, von Mehren, M, Shchaveleva, I, Simmons, H H, Marks, J D, Adams, G P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2576487/ https://www.ncbi.nlm.nih.gov/pubmed/18841159 http://dx.doi.org/10.1038/sj.bjc.6604700 |
Ejemplares similares
-
A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016) -
Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014) -
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
por: Rabia, Emilia, et al.
Publicado: (2023) -
ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
por: Alvarado, Diego, et al.
Publicado: (2017) -
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer
por: Ghasemi, R, et al.
Publicado: (2014)